Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Finished

CATCH Novel T cell therapies against lymphocytic leukaemia

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
1 July 2022 to 31 December 2023
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101081970

What the project is doing

In the project's own words, from its summary on CORDIS.

Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia globally and can rarely be cured. Despite recent advances, the efficacy of promising autologous T cell-based therapies, such as CAR-T technology and bi-/tri-specific antibodies, has been disappointing. This stems from a T cell dysfunction in this disease setting: altered T cell skewing, impaired metabolic plasticity, and disrupted T-cell functioning.

Prof. Arnon Kater's group studies alternative activation pathways to overcome T cell dysfunction and stimulate an immune response. CATCH will explore the technical and commercial feasibility of alternative T-cell activation, through CAR-T and tri-specific antibody technologies. To reach proof-of-concept stage, in this project we will: 1) Validate the efficacy of two applications (CAR-T, tri-specific antibody) by achieving T-cell activation and killing target cells in in-vitro CLL samples and live specimens. 2) Perform a thorough IP landscape analysis, establish Freedom-to-Operate, and define an IP strategy. 3) Engage with key stakeholders to gather feedback and advise from key perspectives (patient, clinical, industry), conduct market research to discover potential customers/industrial partners, analyse competitors and identify a feasible roadmap to commercialisation. 4) Formulate a detailed business case to guide the commercialisation of CATCH.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI